Rapid End-Game Process Development and First GMP Production of MK-7845: An Experimental Antiviral Treatment for COVID-19

已完结 10 由胖子发布于 2024/6/8 21:24:39

DOI:10.1021/acs.oprd.4c00015
作者：Nicholas R. Deprez, Jonathan M. E. Hughes, Shorouk O. Badir, Stasik Popov, Teresa Andreani, Rachel S. Bade, Clara Hartmanshenn, Thomas Tai-min Kwok, Donald R. Gauthier, Jr., Nastaran Salehi Marzijarani, Zeinab Sakhaei, Riki Drout, Steve Castro, David J. Schenk, Charles Wolstenholme, Nilusha Padivitage, Cody Welch, Jason R. Kowalski, Brittany Kassim, Yong Liu, Ryan D. Cohen, Alex M. Confer, Guilherme Dal Poggetto, Andrew P. J. Brunskill, Feng Peng, Ji Qi, Jing Xu, Mingxiang Lin, Jamie M. McCabe Dunn
文献类型：期刊论文
补充材料：只需要正文

American Chemical Society (ACS)

Abstract：We describe the rapid end-game process development for the first good manufacturing process (GMP) delivery of the 3C-like protease inhibitor MK-7845 (1), an experimental treatment for SARS-C

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Chemical Society (ACS)Benchmarking Strategies of Sustainable Process Chemistry Development: Human-Based, Machine Learning, and Quantum Mechanics